375 related articles for article (PubMed ID: 32139179)
21. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.
Chiorean EG; Coveler AL
Drug Des Devel Ther; 2015; 9():3529-45. PubMed ID: 26185420
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
Ercan G; Karlitepe A; Ozpolat B
Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
[TBL] [Abstract][Full Text] [Related]
23. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Cheung PF; Yang J; Fang R; Borgers A; Krengel K; Stoffel A; Althoff K; Yip CW; Siu EHL; Ng LWC; Lang KS; Cham LB; Engel DR; Soun C; Cima I; Scheffler B; Striefler JK; Sinn M; Bahra M; Pelzer U; Oettle H; Markus P; Smeets EMM; Aarntzen EHJG; Savvatakis K; Liffers ST; Lueong SS; Neander C; Bazarna A; Zhang X; Paschen A; Crawford HC; Chan AWH; Cheung ST; Siveke JT
Nat Commun; 2022 Jan; 13(1):156. PubMed ID: 35013174
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
25. Functional and Clinical Proteomic Exploration of Pancreatic Cancer.
Huang P; Gao W; Fu C; Tian R
Mol Cell Proteomics; 2023 Jul; 22(7):100575. PubMed ID: 37209817
[TBL] [Abstract][Full Text] [Related]
26. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
28. Tumor Heterogeneity in Pancreatic Adenocarcinoma.
Cros J; Raffenne J; Couvelard A; Poté N
Pathobiology; 2018; 85(1-2):64-71. PubMed ID: 28787741
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
30. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
[TBL] [Abstract][Full Text] [Related]
31. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
32. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance.
Sherman MH; Beatty GL
Annu Rev Pathol; 2023 Jan; 18():123-148. PubMed ID: 36130070
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data.
Connor AA; Gallinger S
Nat Rev Cancer; 2022 Mar; 22(3):131-142. PubMed ID: 34789870
[TBL] [Abstract][Full Text] [Related]
35. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy.
Bärthel S; Falcomatà C; Rad R; Theis FJ; Saur D
Nat Cancer; 2023 Apr; 4(4):454-467. PubMed ID: 36959420
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.
Damhofer H; Medema JP; Veenstra VL; Badea L; Popescu I; Roelink H; Bijlsma MF
Mol Oncol; 2013 Dec; 7(6):1031-42. PubMed ID: 23998958
[TBL] [Abstract][Full Text] [Related]
37. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
38. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
39. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
[TBL] [Abstract][Full Text] [Related]
40. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma.
Schäfer D; Tomiuk S; Küster LN; Rawashdeh WA; Henze J; Tischler-Höhle G; Agorku DJ; Brauner J; Linnartz C; Lock D; Kaiser A; Herbel C; Eckardt D; Lamorte M; Lenhard D; Schüler J; Ströbel P; Missbach-Guentner J; Pinkert-Leetsch D; Alves F; Bosio A; Hardt O
Nat Commun; 2021 Mar; 12(1):1453. PubMed ID: 33674603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
